1 **Sex and APOE genotype influence Alzheimer's disease tau neuropathology**

2

3 Paula Duarte-Guterman[1], Arianne Y. Albert[2], Cindy K. Barha[3], Liisa A.M. Galea[1], on behalf of

4 the Alzheimer's Disease Neuroimaging Initiative[δ]

5

6 1. Djavad Mowafaghian Centre for Brain Health and Department of Psychology, University of

7 British Columbia, Vancouver, BC, Canada

8 2. Women's Health Research Institute of British Columbia, Vancouver, BC, Canada

9 3. Djavad Mowafaghian Centre for Brain Health and Department of Physical Therapy,

10 University of British Columbia, Vancouver, BC, Canada

11
12
13 Address all correspondence and requests for reprints to:
14 L. A. M. Galea, PhD
15 Djavad Mowafaghian Centre for Brain Health
16 2215 Wesbrook Mall
17 Vancouver, British Columbia
18 V6T 1Z3, Canada
19 E-mail: lgalea@psych.ubc.ca.
20
21
22
23

24 [δ] Data used in preparation of this article were obtained from the Alzheimer's Disease
25 Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within
26 the ADNI contributed to the design and implementation of ADNI and/or provided data but did
27 not participate in analysis or writing of this report. A complete listing of ADNI investigators can
28 be found at: http://adni.loni.usc.edu/wp-
29 content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

ABSTRACT

Alzheimer's disease (AD) is characterised by severe cognitive decline and pathological

changes in the brain (brain atrophy, hyperphosphorylation of tau, and deposition of toxic

amyloid-beta protein). Females have worse neuropathology (AD biomarkers and brain atrophy

rates) and cognitive decline than males, however biological sex can interact with diagnosis (mild

cognitive impairment (MCI) or AD) and APOE genotype (number of ε4 alleles), although there

are discrepancies between studies. Using the ADNI database, we analysed the effect of sex and

APOE genotype (number of ε4 alleles) and sex and diagnosis (cognitively normal (CN), MCI,

AD) on cognition (memory and executive function), hippocampal volume, CSF amyloid beta,

CSF tau and ptau. More males were diagnosed with MCI but there was no sex difference in those

diagnosed with AD, suggesting the progression from CN, MCI to AD may be sex-specific. We

found, consistent with some studies, that females had higher levels of CSF tau-pathology that

was disproportionately affected by APOE genotype compared to males. These results suggest

that sex and APOE genotype effects on AD biomarkers may influence sex differences in

incidence and progression of MCI and AD. We also detected sex differences in hippocampal

volume but the direction was dependent on the method of correction. Females had better memory

(including verbal) scores than males, which may suggest a delay in the onset of cognitive decline

or diagnosis.

Keywords: Sex differences; Alzheimer's disease; APOE genotype; neuroplasticity;

hippocampus; memory.

INTRODUCTION

Alzheimer's disease (AD) is characterized by severe cognitive decline and

neuropathological markers such as brain atrophy, senile plaques, hyperphosphorylation of tau,

and deposition of toxic amyloid-beta protein in the brain (Alzheimer's Association, 2017). The

hippocampus is one of the first brain areas to show atrophy with AD (Apostolova et al., 2006;

Jack et al., 2000; Kidron et al., 1997) and hippocampal atrophy correlates with cognitive decline

(Petersen et al., 2000) and AD pathology (neurofibrillary tangles; Jack et al., 2002). Female sex

and possession of one or two alleles of APOEε4, the strongest genetic risk factor for sporadic

AD, are important non-modifiable risk factors for AD (Riedel et al., 2016). In some studies,

females show greater signs of neuropathology (neurofibrillary tangles, amyloid beta burden),

rates of brain atrophy, including in the hippocampus, and cognitive decline than males but this

may depend on whether females are already cognitively impaired (mild cognitive impairment

(MCI) or AD) and on APOE genotype (Ardekani et al., 2016; Barnes et al., 2005; Cavedo et al.,

2018; Fleisher et al., 2005; Holland et al., 2013; Hua et al., 2010; Irvine et al., 2012; Koran and

Hohman, 2017; Lin et al., 2015; Sundermann et al., 2018; Wang et al., 2019). One allele of

APOEε4 increases the risk of AD in females relative to males at an earlier age (between 65 and

75 years), indicating that the APOE genotype affects males and females differently (Neu et al.,

2017). Previous studies have examined the interaction of APOE genotype and sex on cognitive

function, hippocampal atrophy and AD biomarkers but findings are not consistent (Altmann et

al., 2014; Buckley et al., 2019, 2018; Damoiseaux et al., 2012; Holland et al., 2013; Liu et al.,

2019; Sampedro et al., 2015; Sohn et al., 2018; Wang et al., 2019). In order to improve diagnosis

and treatment including the development of personalised treatments based on sex and genotype,

it is important to understanding why females are at a higher risk and have a higher burden of the

disease.

Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, previous studies found a stronger association between APOEε4 and CSF tau levels in females compared to males (Altmann et al., 2014; Damoiseaux et al., 2012; Liu et al., 2019) but this has not been consistently reported in all ADNI studies (Buckley et al., 2019; Sampedro et al., 2015). In some ADNI studies, females with APOEε4 alleles have steeper hippocampal volume reductions (Holland et al., 2013) and cognitive decline (Wang et al., 2019) compared to males (although see: Buckley et al., 2018; Sohn et al., 2018). Differences in type of statistical analyses, sample size, how many groups were included in the analyses (cognitively healthy, MCI, AD), and types of cognitive tests (types of memory and executive function) are likely reasons for the discrepancies between studies.

In addition, a basic understanding of sex differences in hippocampal function and structure is needed. There are sex differences in certain types of memory that involve the hippocampus in both humans and rodents, although not all studies find this sex difference for a variety of reasons (Yagi and Galea, 2019). Sex differences in executive function have also been found but are again not very large in size or consistent across studies (Grissom and Reyes, 2019). Females perform better in episodic memory tasks related to verbal memory, whereas males perform better in visuopatial-related tasks (meta-analysis by Asperholm et al., 2019; reviewed in Hamson et al., 2016). Some studies find sex differences in hippocampal volume with females having a smaller volume compared to males, but this seems to depend on whether the data were corrected for individual differences in brain volume and which method was used (meta-analysis by Tan et al., 2016). Understanding basic sex differences in hippocampal function and structure is important to determine how they can contribute to sex differences in vulnerability and progression of neurodegenerative diseases like AD.

The objective of this study was to analyse ADNI data to examine sex differences in

cognitive ability (memory and executive function), volume of the hippocampus (using two

different correction factors), and neuropathological markers of AD (CSF amyloid beta, tau, and

phosphorylated tau), and how these may be affected either by APOE genotype (number of ε4

alleles), or dementia status (cognitively normal (CN), MCI, AD). We hypothesized that females

will be more affected by APOE genotype and diagnosis (MCI and AD) and this will be reflected

in worse cognitive scores and AD pathology, and smaller hippocampus volume than males.

METHODS

ADNI database

Data used in the preparation of this article were obtained from the Alzheimer's Disease

Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in

2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner,

MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging

(MRI), positron emission tomography (PET), other biological markers, and clinical and

neuropsychological assessment can be combined to measure the progression of mild cognitive

impairment (MCI) and early Alzheimer's disease (AD). For up-to-date information, see

www.adni-info.org. Data used in this article were downloaded on or before Jan 16, 2019.

Memory, executive function, hippocampal volume, and CSF biomarkers

We included all participants who had the following baseline data: diagnosis in the ADNI

database, cerebrospinal fluid (CSF) levels for amyloid beta, tau and phosphorylated tau (ptau),

underwent a battery of neuropsychological tests, and had a brain MRI scan (total n = 1,460, n=

630 females, n=830 males; Table 1). Data included in our analyses were: demographics (age,

years of education, and ethnicity), baseline diagnosis (cognitively normal, CN; early MCI,

EMCI; late MCI, LMCI; or AD), number of APOE ε4 alleles (0, 1 or 2), ADNI executive

function z-scores, ADNI memory z-scores (using data from the ADNI neuropsychological

battery and validated in Crane et al., 2012; Gibbons et al., 2012), hippocampal volume (mm^3),

CSF amyloid beta (pg/ml), CSF tau (pg/ml), and CSF p-tau (pg/ml). Inclusion and exclusion

criteria are detailed online (http://adni.loni.usc.edu/methods/documents/) (see also Petersen et al.,

2010; Aisen et al., 2010). Briefly, CN participants had normal memory function (measured by

education-adjusted scores on the Wechsler Memory Scale Logical Memory II) and a Clinical

Dementia Rating (CDR) of 0. Amnestic late MCI (LMCI) participants had objective memory

loss (from Wechsler Memory Scale Logical Memory II scores), a CDR of 0.5, preserved daily

activities, and absence of dementia. Early MCI (EMCI) participants had a milder episodic

memory impairment compared to LMCI (Wechsler Memory Scale Logical Memory II scores

~0.5 and 1.5 SD below the mean of CN participants). All AD participants met

NINCDS/ADRDA Alzheimer's Criteria and a CDR of 0.5 or 1.0. The executive function score

included WAIS-R Digit Symbol Substitution, Digit Span Backwards, Trails A and B, Category

Fluency, and Clock Drawing (Gibbons et al., 2012). The composite memory score included Rey

Auditory Verbal Learning Test, AD Assessment Schedule - Cognition, Mini-Mental State

Examination, and Logical Memory data (Crane et al., 2012). Sex differences in hippocampal

volume are influenced by controlling factors such as intracranial volume (Lotze et al., 2019; Tan

et al., 2016). In the present study, we corrected hippocampus volume using two different

methods. The first method (regression method) used the method in Mormino et al. (2014) and

Jack et al. (2012) using the residuals of the linear regression between hippocampal volume and

total intracranial volume. We also compared another widely used volume correction method

(Sohn et al., 2018; Sundermann et al., 2018; meta-analysis by Tan et al., 2016 and references

herein) by dividing hippocampal volume with intracranial volume to directly compare the

different correction methods.

Statistical Methods

We compared all available data for each study variable between the sexes using the

Wilcoxon rank sum test for continuous variables and Fisher's exact test for categorical variables.

We used general linear models to determine the relationships between (1) sex and APOE

genotype or (2) sex and dementia diagnosis as predictor variables, and cognitive ability,

corrected hippocampal volume, and AD biomarkers as dependent variables. Due to the sample

size, we were not able to study sex, APOE and diagnosis in one model. All models included age

as a covariate. All models initially included an interaction between sex and APOE genotype or

sex and dementia diagnosis; if this interaction was not significant, it was removed from the

model to estimate the main effects of sex and APOE genotype or diagnosis. Significance was

based on the likelihood ratio test, and all p-values for comparisons of sex and either APOE or

diagnosis for all outcomes combined were corrected for multiple testing using the Benjamini-

Hochberg false discovery rate method with the family-wise error rate set to 0.05 (Benjamini and

Hochberg, 1995). In total, three p-values per dependent variable were included in each set of

models (interaction term and main effects of sex and APOE or diagnosis) resulting in 21 p-

values corrected (7 dependent variables; Tables 1 to 3) for each of the models (sex and APOE

and sex and diagnosis) for each of the models (sex and APOE and sex and diagnosis). All

regression analyses were carried out in R v3.5.1 (R Core Team, 2018).

 RESULTS

Demographic information

Table 1 gives a summary of the variables for the overall data set (N=1460). Overall,

females were significantly younger and had fewer years of education than males (P<0.0001 for

both). There were more white males than white females in our sample and there were more non-

white females compared to non-white males (P<0.05). In terms of APOE genotype, there were

no sex differences in distribution of APOE genotype with 40% females and 38.8% males

possessing one allele of APOEɛ4 and 11% females and 12% of males possessing two alleles of

APOEɛ4. In the overall data set, the proportion of participants in each of the diagnosis categories

was significantly different for females and males (P<0.05). More females were cognitively

normal than males (26.7% compared to 20.8%, unadjusted P = 0.01) and although there were

more females with a baseline diagnosis of AD compared to males (23.7% compared to 21.7%,

unadjusted P = 0.41), this was not significant. However, there were more males with a diagnosis

of late MCI (39.5% versus 32.5%, unadjusted P=0.007) but not early MCI (18.0% versus 17.1%,

unadjusted P=0.74) compared to females.

Sex and APOE genotype were associated with changes in memory, hippocampus volume, AD

biomarkers

Our first aim was to investigate whether sex and APOE genotype interact to influence

cognitive ability, volume of the hippocampus, and biomarkers of AD. There were significant

interactions between sex and APOEɛ4 genotype for CSF tau, and p-tau (P=0.001 and 0.002,

respectively; Table 2). Tau and p-tau levels were significantly higher in females with one or two

alleles of APOEε4 compared to males (Fig 1 A and B). Although CSF p-tau and tau levels also

increased in males with APOEε4 genotype, they did not rise to the same extent as in females.

Both sex and APOE genotype were independently (main effects of sex or APOE

genotype) associated with memory z-scores and corrected hippocampal volume (Table 2).

Females had higher memory z-scores across all APOE genotypes (P<0.0001; Fig 1 C).

Curiously, females had smaller or larger hippocampi than males depending on the correction

method used: females had smaller corrected hippocampal volume based on the regression

method (Mormino et al., 2014) (P<0.0001; Fig 1 D) but larger hippocampal/intracranial volume

compared to males (P<0.0001; Table 2). These data suggest it is important to consider different

correction factors when studying sex differences in volumes of brain structures. Lower memory

z-scores were associated with increasing number of APOEε4 alleles in both sexes (P<0.0001).

Similarly, corrected hippocampus volume (independent of method of correction) was

significantly lower with increasing number of APOEε4 alleles in both sexes (Ps<0.0001).

Increasing APOEε4 alleles was also associated with lower executive function z-scores

(P<0.0001), and lower CSF amyloid beta (P<0.0001; Table 2; Fig 1 E and F), however there was

no additional association of these variables with sex.

Sex and diagnosis were associated with changes in memory, hippocampus volume, and AD

biomarkers

We next tested whether sex and dementia status (CN, MCI, and AD) influenced cognitive

ability, corrected hippocampal volume, and CSF biomarkers of AD. There were no significant

interactions between sex and diagnosis for any of the tested variables (memory, executive

function, corrected hippocampal volume, CSF tau, p-tau, and amyloid beta). However, overall

both sex and diagnosis were independently associated with memory z-scores, corrected

hippocampal volume and CSF tau and p-tau (Table 3). As expected based on the analyses with

APOE genotype, females had higher memory z-scores (P<0.0001), smaller corrected

hippocampus volume (P<0.0001) but larger hippocampus/intracranial volume ratio (P<0.0001;

Table 3), and higher tau and p-tau compared to males (Ps<0.0001), irrespective of diagnosis

(Table 3). As expected, increasing severity of diagnosis was associated with lower memory and

executive function z-scores (Ps<0.0001), smaller corrected hippocampus volume (Ps<0.0001;

independent of correction method), lower CSF amyloid beta (P<0.0001), and higher CSF tau and

p-tau irrespective of sex (Ps<0.0001; Fig 2 A-F).

DISCUSSION

In the present study, we found that CSF tau pathology was disproportionately elevated by

APOEε4 genotype in females compared to males. However, diagnosis and APOE genotype were

independently associated with reduced memory and executive function scores, corrected

hippocampal volume and reduced CSF amyloid beta which was similar in males and females.

Furthermore, there were main effects of sex as females had higher tau-related pathology

compared to males. Interestingly, depending on the correction method, females had either

smaller or larger hippocampus volume compared to males. Finally, we found that females had

better memory scores, even after adjusting for age, which may contribute to their delayed

diagnosis (Sundermann et al., 2017). In this ADNI cohort, significantly more males presented

with a diagnosis of MCI whereas there was no sex difference in the number of participants

diagnosed with AD, suggestive of sex differences in transitions to MCI and to AD. It is

interesting to note that population-based studies find prevalence of MCI is higher in males

whereas prevalence of AD is higher in females (Mielke et al., 2014; Petersen et al., 2010;

Winblad et al., 2016), although not all studies agree in the higher prevalence or incidence of AD

in females (Jack et al., 2019; reviewed in Nebel et al., 2018). Previous work has demonstrated

sex differences in rates of AD and symptoms of AD (reviewed in Ferretti et al., 2018; Mielke et

al., 2014; Nebel et al., 2018), and our current study suggests that certain AD biomarkers (CSF

tau but not CSF amyloid beta) are different between males and females between genotypes.

These data provide clues as to how these sex differences in biomarkers of neuropathology may

inform on sex differences in AD lifetime risk and progression.

Females showed greater tau neuropathology disproportionately affected by APOE genotype

In the present study, we found that females have significantly higher baseline tau and p-

tau levels in CSF than males, which is in agreement with a recent ADNI study (Sundermann et

al., 2018) and with a mouse AD model (mutant tau and APP trangenic mice, Lewis et al., 2001).

CSF tau and p-tau are indicative of the formation of neurofibrillary tangles and AD pathology

(Blennow et al., 2015; Henriques et al., 2018). Our findings disagree with an earlier ADNI study

(Holland et al., 2013), which may be due to our increased sample size. We found that levels of

tau and p-tau were disproportionately elevated with APOEε4 allele expression in females

compared to males. Previous studies have found a significant interaction between sex and APOE

genotype on levels of CSF tau in MCI (Altmann et al., 2014) but not in cognitively healthy

individuals (Altmann et al., 2014; Buckley et al., 2019; Sampedro et al., 2015; but see

Damoiseaux et al., 2012). Our data extends these data by adding that the interaction with sex and

APOE genotype is also seen in individuals with AD. A meta-analysis that included data from

ADNI also found a stronger association between APOEε4 and tau levels in females compared to

males (Hohman et al., 2018) but interestingly this association is not present in all ADNI studies

which may depend on sample size, type of statistical analysis, and the diagnosis groups included

in the analyses (Buckley et al., 2019; Sampedro et al., 2015). Previous studies indicate that

females with the APOEε4 allele are at a greater risk for developing AD than are males with this

allele (Altmann et al., 2014; Neu et al., 2017), and sex differences in tau and p-tau may be one

underlying mechanism by which this occurs but further replication with additional and larger

populations are needed. Levels of CSF tau are hypothesized to increase after CSF amyloid beta

declines and amyloid beta aggregates and deposits in the brain (Blennow et al., 2015). However,

in this study, although we found sex differences in CSF tau and p-tau levels, no significant

differences were seen in CSF amyloid beta after controlling for age (see below) indicating that

the pathway may be different in females compared to males or that the timeline of tau and

amyloid beta deposition may not be consistent.

Females have a higher lifetime risk of AD than males and show greater cognitive decline

with AD than males (reviewed by Ferretti et al., 2018; Mielke et al., 2014; Nebel et al., 2018).

The disproportionate effect of APOEε4 genotype on tau-related pathology in females supports

the idea that females have a higher burden of the disease dependent on APOE genotype.

Intriguingly, males are more likely to be diagnosed with MCI compared to females (Jack et al.,

2019; Mielke et al., 2014; Petersen et al., 2000), whereas females progress faster from MCI to

AD (Lin et al., 2015). These findings are similar to those in the current study as we found more

males than females diagnosed with MCI but no sex difference in AD, suggesting that females

"catch up" to males. Sex differences in tau-related pathology found in the current study may be

the underlying mechanism for this accelerated transition.

Females had better memory scores than males

As expected, we found that increasing APOEε4 alleles and AD diagnosis was associated

with reduced memory and executive function scores consistent with past literature (Buckner,

2004; Ewers et al., 2012; Mungas et al., 2010; Petersen et al., 2000). Surprisingly, although

females have higher levels of tau and p-tau, they presented with better memory and executive

function scores than males, regardless of diagnosis and APOE genotype. Previous studies found

that females have better verbal memory compared to males across diagnoses (CN, Jack et al.,

2015; MCI and AD, Sundermann et al., 2018, 2016). Here, we used the ADNI memory score

developed by Crane et al. (2012) to detect abnormal memory including language, attention, and

logical memory so it is possible that verbal memory may be driving the sex difference favouring

females in the present study. In contrast, Buckley et al. (2018) found no sex differences using a

composite cognitive score that includes memory and executive function (Preclinical Alzheimer's

Cognitive Composite score with semantic processing, PACC5) using ADNI and two other

cohorts. Altogether, we found that in females CSF tau pathology was increased but memory

scores, which included verbal memory, were higher compared to males suggesting females have

a reserve against brain damage that delays either the onset of cognitive decline (Stern, 2002) or

diagnosis (Sundermann et al., 2017). However, once cognitive decline begins, females show

higher rates of declines compared to males (Buckley et al., 2018; Holland et al., 2013; Hua et al.,

2010) perhaps because the underlying pathology is elevated in females.

Sex differences in hippocampal volume depended on correction method

We found that increasing APOEε4 alleles and AD diagnosis was associated with reduced

corrected hippocampal volume (both methods of correction) consistent with previous literature

(Apostolova et al., 2006; Buckner, 2004; Ewers et al., 2012; Jack et al., 2000; Li et al., 2016;

Petersen et al., 2000; Pievani et al., 2011; Shi et al., 2014). Curiously, depending on the

correction method, females had larger or smaller hippocampal volume compared to males.

Females had smaller corrected hippocampal volume using the residuals of the linear regression

between hippocampal volume and total intracranial volume (regression method by Mormino et

al., 2014; Jack et al., 2012) but larger ratio of hippocampal/intracranial volume compared to

males (method used in Sohn et al., 2018; Sundermann et al., 2018; Tan et al., 2016). Previous

studies have suggested that there are sex differences in hippocampal volume, favoring males, but

the sex differences depend on whether hippocampal volume is corrected for by intracranial

volume or total brain volume and the method of correction (Tan et al., 2016). In a number of

studies, including the present study, males have a larger hippocampus without correcting for

intracranial volume (Cavedo et al., 2018; Jack et al., 2015; Murphy et al., 1996; Ritchie et al.,

2018; Sohn et al., 2018; Sundermann et al., 2018; Tan et al., 2016). However after correcting for

intracranial volume using the regression model, studies have found females have larger (Jack et

al., 2015), smaller (present study) or no difference (Cavedo et al., 2018; Tan et al., 2016) in

corrected hippocampal volume compared to males. Using the ratio method, Sohn et al. (2018),

Sundermann et al. (2018), Murphy et al. (1996) and the current study found that females had

larger hippocampal volumes compared to males. In their meta-analysis, Tan et al. (2016)

conclude that sex differences in hippocampal volume are modest and highly depend on

correction method and this is supported by our findings. These results have important

implications for understanding sex differences in diseases that influence the integrity of the

hippocampus as they lead to very different conclusions regarding hippocampal plasticity. We

suggest future research should report uncorrected as well as corrected volumes using multiple

methods.

Regardless of hippocampal volume, volume loss is greater in aging females (Ardekani et

al., 2016; Koran et al., 2017; Murphy et al., 1996) and in females with one or two APOEε4

alleles (Fleisher et al., 2005). Although in the present study we did not examine longitudinal

data, we found that increasing APOEε4 alleles reduced corrected hippocampal volume similarly

in males and females. In contrast, when CN, MCI and AD individuals were analysed separately

in the ADNI database, APOEε4 was associated with a smaller corrected hippocampal volume in

CN males only (Sundermann et al., 2018) and greater sex differences in longitudinal changes as

females with low CSF amyloid beta had more hippocampal atrophy and faster decline in memory

and executive function than males (Koran et al., 2017). Therefore, sex and APOE genotype can

interact to affect corrected hippocampal volume reduction with age in certain subgroups and

across time (e.g., in CN or individuals with low CSF amyloid beta). Differences in results

between studies are likely due to differences in statistical analyses (e.g., analysing diagnosis

groups separately, partitioning the data based on amyloid beta levels, and differences in

covariates included) and/or whether longitudinal data analyses are included.

AD affects amyloid beta similarly in both sexes

We found that AD diagnosis was associated with lower CSF amyloid beta, as expected,

and this was irrespective of sex, which indicates greater amyloid deposition with AD (Henriques

et al., 2018). These findings are consistent with data from studies in cognitively healthy

individuals (Buckley et al., 2018; Jack et al., 2015). Other studies have found using PET that

males have higher amyloid beta levels or lower amyloid beta burden compared to females

dependent on APOE genotype (Sundermann et al., 2018) or in cognitively normal adults in the

anterior cingulate (Cavedo et al., 2018). In this study, we used CSF amyloid beta data which

detect abnormal amyloid deposition earlier than amyloid beta by PET (reviewed in Blennow et

al., 2015). Thus, taken together, sex differences in amyloid beta may be detected in specific brain

regions and later in the disease, although more research is needed investigating sex differences in

AD biomarkers.

Limitations

The ADNI data are not representative of the population as it is mostly composed of white

and highly educated individuals. Ethnicity (Fitten et al., 2014; Mayeda et al., 2016; Steenland et

al., 2016) and education (Sharp and Gatz, 2011) can affect incidence, prevalence and age of AD

onset. Therefore, our conclusions may not apply to more ethnically and socially diverse

populations. In this cohort, the proportion of participants in the different APOEε4 allele groups is

correlated with AD diagnosis. Future research with a larger cohort is required to test in one

model how sex, APOE genotype and diagnosis interact together.

CONCLUSION

AD biomarkers, CSF tau and p-tau but not amyloid beta, were disproportionately affected

by APOE genotype in females compared to males supporting sex differences in the manifestation

of AD. Hippocampal volumes were different between the sexes but the direction was dependent

on the method of correction. Interestingly, although females in this cohort had elevated AD

biomarkers, they also had higher memory function scores compared to males, regardless of

APOE genotype and dementia diagnosis. Therefore, it is possible that females may have a

reserve that protects the brain from damage to delay cognitive decline or delay diagnosis.

<u>ACKNOWLEDGMENTS</u>

Data collection and sharing for this project was funded by the Alzheimer's Disease

Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD

ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the

National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering,

and through generous contributions from the following: AbbVie, Alzheimer's Association;

Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-

Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli

Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company

Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy

Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development

LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx

Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal

Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian

Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private

sector contributions are facilitated by the Foundation for the National Institutes of Health

(www.fnih.org). The grantee organization is the Northern California Institute for Research and

Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the

University of Southern California. ADNI data are disseminated by the Laboratory for Neuro

Imaging at the University of Southern California. Funding for this study was provided by a

Canadian Institutes of Health Research (CHIR) grant to LAMG (PJT-148662). PDG is funded by

the Alzheimer's Association of the USA and Brain Canada with the financial support of Health

Canada through the Brain Canada Research Fund (AARF-17-529705). The views expressed

herein do not necessarily represent the views of the Minister of Health or the Government of

Canada. We thank Elizabeth Perez for help with data organization.

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

REFERENCES

Altmann, A., Tian, L., Henderson, V.W., Greicius, M.D., 2014. Sex modifies the APOE-related
risk of developing Alzheimer disease. Annals of Neurology 75, 563–573.
https://doi.org/10.1002/ana.24135
Alzheimer's Association, 2017. 2017 Alzheimer's disease facts and figures. Alzheimer's &
Dementia 13, 325–373. https://doi.org/10.1016/j.jalz.2017.02.001
Apostolova, L.G., Dutton, R.A., Dinov, I.D., Hayashi, K.M., Toga, A.W., Cummings, J.L.,
Thompson, P.M., 2006. Conversion of mild cognitive impairment to Alzheimer disease
predicted by hippocampal atrophy maps. Arch. Neurol. 63, 693–699.
https://doi.org/10.1001/archneur.63.5.693
Ardekani, B.A., Convit, A., Bachman, A.H., 2016. Analysis of the MIRIAD Data Shows Sex
Differences in Hippocampal Atrophy Progression. J. Alzheimers Dis. 50, 847–857.
https://doi.org/10.3233/JAD-150780
Asperholm, M., Högman, N., Rafi, J., Herlitz, A., 2019. What did you do yesterday? A meta-
analysis of sex differences in episodic memory. Psychol Bull 145, 785–821.
https://doi.org/10.1037/bul0000197
Barnes, L.L., Wilson, R.S., Bienias, J.L., Schneider, J.A., Evans, D.A., Bennett, D.A., 2005. Sex
differences in the clinical manifestations of Alzheimer disease pathology. Arch. Gen.
Psychiatry 62, 685–691. https://doi.org/10.1001/archpsyc.62.6.685
Benjamini, Y., Hochberg, Y., 1995. Controlling the False Discovery Rate: A Practical and
Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B
(Methodological) 57, 289–300.
Blennow, K., Dubois, B., Fagan, A.M., Lewczuk, P., de Leon, M.J., Hampel, H., 2015. Clinical
utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.
Alzheimer's & Dementia 11, 58–69. https://doi.org/10.1016/j.jalz.2014.02.004
Buckley, R.F., Mormino, E.C., Amariglio, R.E., Properzi, M.J., Rabin, J.S., Lim, Y.Y., Papp,
K.V., Jacobs, H.I.L., Burnham, S., Hanseeuw, B.J., Doré, V., Dobson, A., Masters, C.L.,

Waller, M., Rowe, C.C., Maruff, P., Donohue, M.C., Rentz, D.M., Kirn, D., Hedden, T., Chhatwal, J., Schultz, A.P., Johnson, K.A., Villemagne, V.L., Sperling, R.A., 2018. Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimer's & Dementia 14, 1193–1203. https://doi.org/10.1016/j.jalz.2018.04.010

Buckley, R.F., Mormino, E.C., Chhatwal, J., Schultz, A.P., Rabin, J.S., Rentz, D.M., Acar, D., Properzi, M.J., Dumurgier, J., Jacobs, H., Gomez-Isla, T., Johnson, K.A., Sperling, R.A., Hanseeuw, B.J., 2019. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiology of Aging 78, 178–185. https://doi.org/10.1016/j.neurobiolaging.2019.02.019

Buckner, R.L., 2004. Memory and Executive Function in Aging and AD: Multiple Factors that Cause Decline and Reserve Factors that Compensate. Neuron 44, 195–208. https://doi.org/10.1016/j.neuron.2004.09.006

Cavedo, E., Chiesa, P.A., Houot, M., Ferretti, M.T., Grothe, M.J., Teipel, S.J., Lista, S., Habert, M.-O., Potier, M.-C., Dubois, B., Hampel, H., Bakardjian, H., Benali, H., Bertin, H., Bonheur, J., Boukadida, L., Boukerrou, N., Cavedo, E., Chiesa, P., Colliot, O., Dubois, B., Dubois, M., Epelbaum, S., Gagliardi, G., Genthon, R., Habert, M.-O., Hampel, H., Houot, M., Kas, A., Lamari, F., Levy, M., Lista, S., Metzinger, C., Mochel, F., Nyasse, F., Poisson, C., Potier, M.-C., Revillon, M., Santos, A., Andrade, K.S., Sole, M., Surtee, M., de Schotten, M.T., Vergallo, A., Younsi, N., Aguilar, L.F., Babiloni, C., Baldacci, F., Benda, N., Black, K.L., Bokde, A.L.W., Bonuccelli, U., Broich, K., Bun, R.S., Cacciola, F., Castrillo, J., Cavedo, E., Ceravolo, R., Chiesa, P.A., Colliot, O., Coman, C.-M., Corvol, J.-C., Cuello, A.C., Cummings, J.L., Depypere, H., Dubois, B., Duggento, A., Durrleman, S., Escott-Price, V., Federoff, H., Ferretti, M.T., Fiandaca, M., Frank, R.A., Garaci, F., Genthon, R., George, N., Giorgi, F.S., Graziani, M., Haberkamp, M., Habert, M.-O., Hampel, H., Herholz, K., Karran, E., Kim, S.H., Koronyo, Y., Koronyo-Hamaoui, M., Lamari, F., Langevin, T., Lehéricy, S., Lista, S., Lorenceau, J., Mapstone, M., Neri, C., Nisticò, R., Nyasse-Messene, F., O'bryant, S.E., Perry, G., Ritchie, C., Rojkova, K., Rossi, S., Saidi, A., Santarnecchi, E., Schneider, L.S., Sporns, O., Toschi, N., Verdooner, S.R., Vergallo, A., Villain, N., Welikovitch, L.A., Woodcock, J., Younesi, E., 2018. Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. Alzheimer's & Dementia 14, 1204–1215. https://doi.org/10.1016/j.jalz.2018.05.014

Crane, P.K., Carle, A., Gibbons, L.E., Insel, P., Mackin, R.S., Gross, A., Jones, R.N., Mukherjee, S., Curtis, S.M., Harvey, D., Weiner, M., Mungas, D., Alzheimer's Disease Neuroimaging Initiative, 2012. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 6, 502–516. https://doi.org/10.1007/s11682-012-9186-z

Damoiseaux, J.S., Seeley, W.W., Zhou, J., Shirer, W.R., Coppola, G., Karydas, A., Rosen, H.J., Miller, B.L., Kramer, J.H., Greicius, M.D., Alzheimer's Disease Neuroimaging Initiative, 2012. Gender modulates the APOE ε4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J. Neurosci. 32, 8254–8262. https://doi.org/10.1523/JNEUROSCI.0305-12.2012

Ewers, M., Walsh, C., Trojanowski, J.Q., Shaw, L.M., Petersen, R.C., Jack, C.R., Feldman, H.H., Bokde, A.L.W., Alexander, G.E., Scheltens, P., Vellas, B., Dubois, B., Weiner, M., Hampel, H., 2012. Prediction of conversion from mild cognitive impairment to

Alzheimer's disease dementia based upon biomarkers and neuropsychological test
performance. Neurobiology of Aging 33, 1203-1214.e2.
https://doi.org/10.1016/j.neurobiolaging.2010.10.019
Ferretti, M.T., Iulita, M.F., Cavedo, E., Chiesa, P.A., Schumacher Dimech, A., Santuccione
Chadha, A., Baracchi, F., Girouard, H., Misoch, S., Giacobini, E., Depypere, H., Hampel,
H., 2018. Sex differences in Alzheimer disease — the gateway to precision medicine.
Nature Reviews Neurology 14, 457–469. https://doi.org/10.1038/s41582-018-0032-9
Fitten, L.J., Ortiz, F., Fairbanks, L., Bartzokis, G., Lu, P., Klein, E., Coppola, G., Ringman, J.,
2014. Younger age of dementia diagnosis in a Hispanic population in southern California.
Int J Geriatr Psychiatry 29, 586–593. https://doi.org/10.1002/gps.4040
Fleisher, A., Grundman, M., Jack, C.R., Petersen, R.C., Taylor, C., Kim, H.T., Schiller, D.H.B.,
Bagwell, V., Sencakova, D., Weiner, M.F., DeCarli, C., DeKosky, S.T., Dyck, C.H. van,
Thal, L.J., 2005. Sex, Apolipoprotein E ε4 Status, and Hippocampal Volume in Mild
Cognitive Impairment. Arch Neurol 62, 953–957.
https://doi.org/10.1001/archneur.62.6.953
Gibbons, L.E., Carle, A.C., Mackin, R.S., Harvey, D., Mukherjee, S., Insel, P., Curtis, S.M.,
Mungas, D., Crane, P.K., Alzheimer's Disease Neuroimaging Initiative, 2012. A
composite score for executive functioning, validated in Alzheimer's Disease
Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment.
Brain Imaging Behav 6, 517–527. https://doi.org/10.1007/s11682-012-9176-1
Grissom, N.M., Reyes, T.M., 2019. Let's call the whole thing off: evaluating gender and sex
differences in executive function. Neuropsychopharmacology 44, 86–96.
https://doi.org/10.1038/s41386-018-0179-5
Hamson, D.K., Roes, M.M., Galea, L.A.M., 2016. Sex Hormones and Cognition:
Neuroendocrine Influences on Memory and Learning, in: Terjung, R. (Ed.),
Comprehensive Physiology. John Wiley & Sons, Inc., Hoboken, NJ, USA, pp. 1295–
1337. https://doi.org/10.1002/cphy.c150031
Henriques, A.D., Benedet, A.L., Camargos, E.F., Rosa-Neto, P., Nóbrega, O.T., 2018. Fluid and
imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.
Experimental Gerontology 107, 169–177. https://doi.org/10.1016/j.exger.2018.01.002
Hohman, T.J., Dumitrescu, L., Barnes, L.L., Thambisetty, M., Beecham, G., Kunkle, B., Gifford,
K.A., Bush, W.S., Chibnik, L.B., Mukherjee, S., Jager, P.L.D., Kukull, W., Crane, P.K.,
Resnick, S.M., Keene, C.D., Montine, T.J., Schellenberg, G.D., Haines, J.L., Zetterberg,
H., Blennow, K., Larson, E.B., Johnson, S.C., Albert, M., Bennett, D.A., Schneider, J.A.,
Jefferson, A.L., 2018. Sex-Specific Association of Apolipoprotein E With Cerebrospinal
Fluid Levels of Tau. JAMA Neurol 75, 989–998.
https://doi.org/10.1001/jamaneurol.2018.0821
Holland, D., Desikan, R.S., Dale, A.M., McEvoy, L.K., Alzheimer's Disease Neuroimaging
Initiative, 2013. Higher rates of decline for women and apolipoprotein E epsilon4
carriers. AJNR Am J Neuroradiol 34, 2287–2293. https://doi.org/10.3174/ajnr.A3601
Hua, X., Hibar, D.P., Lee, S., Toga, A.W., Jack, C.R., Weiner, M.W., Thompson, P.M., 2010.
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans.
Neurobiology of Aging 31, 1463–1480.
https://doi.org/10.1016/j.neurobiolaging.2010.04.033

Irvine, K., Laws, K.R., Gale, T.M., Kondel, T.K., 2012. Greater cognitive deterioration in
women than men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol 34,
989–998. https://doi.org/10.1080/13803395.2012.712676
Jack, C.R., Dickson, D.W., Parisi, J.E., Xu, Y.C., Cha, R.H., O'Brien, P.C., Edland, S.D., Smith,
G.E., Boeve, B.F., Tangalos, E.G., Kokmen, E., Petersen, R.C., 2002. Antemortem MRI
Findings Correlate with Hippocampal Neuropathology in Typical Aging and Dementia.
Neurology 58, 750–757.
Jack, C.R., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., Kantarci, K.,
Gunter, J.L., Senjem, M.L., Ivnik, R.J., Roberts, R.O., Rocca, W.A., Boeve, B.F.,
Petersen, R.C., 2012. An operational approach to National Institute on Aging–
Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology
71, 765–775. https://doi.org/10.1002/ana.22628
Jack, C.R., Petersen, R.C., Xu, Y., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F.,
Tangalos, E.G., Kokmen, E., 2000. Rates of hippocampal atrophy correlate with change
in clinical status in aging and AD. Neurology 55, 484–489.
https://doi.org/10.1212/wnl.55.4.484
Jack, C.R., Therneau, T.M., Weigand, S.D., Wiste, H.J., Knopman, D.S., Vemuri, P., Lowe, V.J.,
Mielke, M.M., Roberts, R.O., Machulda, M.M., Graff-Radford, J., Jones, D.T., Schwarz,
C.G., Gunter, J.L., Senjem, M.L., Rocca, W.A., Petersen, R.C., 2019. Prevalence of
Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National
Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurol.
https://doi.org/10.1001/jamaneurol.2019.1971
Jack, C.R., Wiste, H.J., Weigand, S.D., Knopman, D.S., Vemuri, P., Mielke, M.M., Lowe, V.,
Senjem, M.L., Gunter, J.L., Machulda, M.M., Gregg, B.E., Pankratz, V.S., Rocca, W.A.,
Petersen, R.C., 2015. Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and
β-Amyloid Across the Adult Life Span. JAMA Neurol 72, 511–519.
https://doi.org/10.1001/jamaneurol.2014.4821
Kidron, D., Black, S.E., Stanchev, P., Buck, B., Szalai, J.P., Parker, J., Szekely, C., Bronskill,
M.J., 1997. Quantitative MR volumetry in Alzheimer's disease: Topographic markers
and the effects of sex and education. Neurology 49, 1504–1512.
https://doi.org/10.1212/WNL.49.6.1504
Koran, M.E.I., Hohman, T.J., 2017. Sex differences in the association between AD biomarkers
and cognitive decline. Brain Imaging and Behavior 11, 205–213.
https://doi.org/10.1007/s11682-016-9523-8
Koran, M.E.I., Wagener, M., Hohman, T.J., Alzheimer's Neuroimaging Initiative, 2017. Sex
differences in the association between AD biomarkers and cognitive decline. Brain
Imaging Behav 11, 205–213. https://doi.org/10.1007/s11682-016-9523-8
Lewis, J., Dickson, D.W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara,
N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, M., McGowan, E., 2001.
Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and
APP. Science, New Series 293, 1487–1491.
Li, B., Shi, J., Gutman, B.A., Baxter, L.C., Thompson, P.M., Caselli, R.J., Wang, Y., 2016.
Influence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-
Based ADNI Study. PLoS One 11. https://doi.org/10.1371/journal.pone.0152901
Lin, K.A., Choudhury, K.R., Rathakrishnan, B.G., Marks, D.M., Petrella, J.R., Doraiswamy,
P.M., 2015. Marked gender differences in progression of mild cognitive impairment over

8 years. Alzheimer's & Dementia: Translational Research & Clinical Interventions 1, 103–110. https://doi.org/10.1016/j.trci.2015.07.001

Liu, M., Paranjpe, M.D., Zhou, X., Duy, P.Q., Goyal, M.S., Benzinger, T.L.S., Lu, J., Wang, R., Zhou, Y., 2019. Sex modulates the ApoE ε4 effect on brain tau deposition measured by 18F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics 9, 4959–4970. https://doi.org/10.7150/thno.35366

Lotze, M., Domin, M., Gerlach, F.H., Gaser, C., Lueders, E., Schmidt, C.O., Neumann, N., 2019. Novel findings from 2,838 Adult Brains on Sex Differences in Gray Matter Brain Volume. Scientific Reports 9, 1671. https://doi.org/10.1038/s41598-018-38239-2

Mayeda, E.R., Glymour, M.M., Quesenberry, C.P., Whitmer, R.A., 2016. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimer's & Dementia 12, 216–224. https://doi.org/10.1016/j.jalz.2015.12.007

Mielke, M.M., Vemuri, P., Rocca, W.A., 2014. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol 6, 37–48. https://doi.org/10.2147/CLEP.S37929

Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., Johnson, K.A., Sperling, R.A., 2014. Synergistic Effect of β-Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. JAMA Neurol 71, 1379–1385. https://doi.org/10.1001/jamaneurol.2014.2031

Mungas, D., Beckett, L., Harvey, D., Farias, S.T., Reed, B., Carmichael, O., Olichney, J., Miller, J., DeCarli, C., 2010. Heterogeneity of Cognitive Trajectories in Diverse Older Person. Psychol Aging 25, 606–619. https://doi.org/10.1037/a0019502

Murphy, D.G.M., DeCarli, C., Mclntosh, A.R., Daly, E., Mentis, M.J., Pietrini, P., Szczepanik, J., Schapiro, M.B., Grady, C.L., Horwitz, B., Rapoport, S.I., 1996. Sex Differences in Human Brain Morphometry and Metabolism: An In Vivo Quantitative Magnetic Resonance Imaging and Positron Emission Tomography Study on the Effect of Aging. Arch Gen Psychiatry 53, 585–594. https://doi.org/10.1001/archpsyc.1996.01830070031007

Nebel, R.A., Aggarwal, N.T., Barnes, L.L., Gallagher, A., Goldstein, J.M., Kantarci, K., Mallampalli, M.P., Mormino, E.C., Scott, L., Yu, W.H., Maki, P.M., Mielke, M.M., 2018. Understanding the impact of sex and gender in Alzheimer's disease: A call to action. Alzheimer's & Dementia 14, 1171–1183. https://doi.org/10.1016/j.jalz.2018.04.008

Neu, S.C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.-S., Romero, K., Arneric, S.P., Redolfi, A., Orlandi, D., Frisoni, G.B., Au, R., Devine, S., Auerbach, S., Espinosa, A., Boada, M., Ruiz, A., Johnson, S.C., Koscik, R., Wang, J.-J., Hsu, W.-C., Chen, Y.-L., Toga, A.W., 2017. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2017.2188

Petersen, R.C., Jack, C.R., Xu, Y.C., Waring, S.C., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Tangalos, E.G., Boeve, B.F., Kokmen, E., 2000. Memory and MRI-based hippocampal volumes in aging and AD. Neurology 54, 581–587. https://doi.org/10.1212/wnl.54.3.581

Petersen, R.C., Roberts, R.O., Knopman, D.S., Geda, Y.E., Cha, R.H., Pankratz, V.S., Boeve, B.F., Tangalos, E.G., Ivnik, R.J., Rocca, W.A., 2010. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 75, 889–897. https://doi.org/10.1212/WNL.0b013e3181f11d85

Pievani, M., Galluzzi, S., Thompson, P.M., Rasser, P.E., Bonetti, M., Frisoni, G.B., 2011. APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease. Neuroimage 55, 909–919. https://doi.org/10.1016/j.neuroimage.2010.12.081

R Core Team, 2018. R: A language and environment for statistical   computing. R Foundation for Statistical Computing, Vienna, Austria. R Foundation for Statistical Computing, Vienna, Austria.

Riedel, B.C., Thompson, P.M., Brinton, R.D., 2016. Age, APOE and sex: Triad of risk of Alzheimer's disease. The Journal of Steroid Biochemistry and Molecular Biology 160, 134–147. https://doi.org/10.1016/j.jsbmb.2016.03.012

Ritchie, S.J., Cox, S.R., Shen, X., Lombardo, M.V., Reus, L.M., Alloza, C., Harris, M.A., Alderson, H.L., Hunter, S., Neilson, E., Liewald, D.C.M., Auyeung, B., Whalley, H.C., Lawrie, S.M., Gale, C.R., Bastin, M.E., McIntosh, A.M., Deary, I.J., 2018. Sex Differences in the Adult Human Brain: Evidence from 5216 UK Biobank Participants. Cereb Cortex 28, 2959–2975. https://doi.org/10.1093/cercor/bhy109

Sampedro, F., Vilaplana, E., de Leon, M.J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M., Sala, I., Sánchez-Saudinos, M.-B., Antón-Aguirre, S., Morenas-Rodríguez, E., Camacho, V., Falcón, C., Pavía, J., Ros, D., Clarimón, J., Blesa, R., Lleó, A., Fortea, J., Alzheimer's Disease Neuroimaging Initiative, 2015. APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget 6, 26663–26674. https://doi.org/10.18632/oncotarget.5185

Sharp, E.S., Gatz, M., 2011. The Relationship between Education and Dementia An Updated Systematic Review. Alzheimer Dis Assoc Disord 25, 289–304. https://doi.org/10.1097/WAD.0b013e318211c83c

Shi, J., Leporé, N., Gutman, B.A., Thompson, P.M., Baxter, L.C., Caselli, R.J., Wang, Y., Alzheimer's Disease Neuroimaging Initiative, 2014. Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study. Hum Brain Mapp 35, 3903–3918. https://doi.org/10.1002/hbm.22447

Sohn, D., Shpanskaya, K., Lucas, J.E., Petrella, J.R., Saykin, A.J., Tanzi, R.E., Samatova, N.F., Doraiswamy, P.M., 2018. Sex Differences in Cognitive Decline in Subjects with High Likelihood of Mild Cognitive Impairment due to Alzheimer's disease. Scientific Reports 8, 7490. https://doi.org/10.1038/s41598-018-25377-w

Steenland, K., Goldstein, F.C., Levey, A., Wharton, W., 2016. A Meta-Analysis of Alzheimer's Disease Incidence and Prevalence Comparing African-Americans and Caucasians. J. Alzheimers Dis. 50, 71–76. https://doi.org/10.3233/JAD-150778

Stern, Y., 2002. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 8, 448–460.

Sundermann, E.E., Biegon, A., Rubin, L.H., Lipton, R.B., Landau, S., Maki, P.M., Alzheimer's Disease Neuroimaging Initiative, 2017. Does the Female Advantage in Verbal Memory Contribute to Underestimating Alzheimer's Disease Pathology in Women versus Men? J. Alzheimers Dis. 56, 947–957. https://doi.org/10.3233/JAD-160716

Sundermann, E.E., Biegon, A., Rubin, L.H., Lipton, R.B., Mowrey, W., Landau, S., Maki, P.M., 2016. Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. Neurology 86, 1368–1376. https://doi.org/10.1212/WNL.0000000000002570

Sundermann, E.E., Tran, M., Maki, P.M., Bondi, M.W., 2018. Sex differences in the association between apolipoprotein E ε4 allele and Alzheimer's disease markers. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 10, 438–447. https://doi.org/10.1016/j.dadm.2018.06.004

Tan, A., Ma, W., Vira, A., Marwha, D., Eliot, L., 2016. The human hippocampus is not sexually-dimorphic: Meta-analysis of structural MRI volumes. NeuroImage 124, 350–366. https://doi.org/10.1016/j.neuroimage.2015.08.050

Wang, X., Zhou, W., Ye, T., Lin, X., Zhang, J., Initiative, for A.D.N., 2019. Sex Difference in the Association of APOE4 with Memory Decline in Mild Cognitive Impairment. Journal of Alzheimer's Disease 69, 1161–1169. https://doi.org/10.3233/JAD-181234

Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., Fratiglioni, L., Frisoni, G.B., Gauthier, S., Georges, J., Graff, C., Iqbal, K., Jessen, F., Johansson, G., Jönsson, L., Kivipelto, M., Knapp, M., Mangialasche, F., Melis, R., Nordberg, A., Rikkert, M.O., Qiu, C., Sakmar, T.P., Scheltens, P., Schneider, L.S., Sperling, R., Tjernberg, L.O., Waldemar, G., Wimo, A., Zetterberg, H., 2016. Defeating Alzheimer's disease and other dementias: a priority for European science and society. The Lancet Neurology 15, 455–532. https://doi.org/10.1016/S1474-4422(16)00062-4

Yagi, S., Galea, L.A.M., 2019. Sex differences in hippocampal cognition and neurogenesis. Neuropsychopharmacology 44, 200–213. https://doi.org/10.1038/s41386-018-0208-4

 FIGURE CAPTIONS

Figure 1. A. CSF tau (pg/ml), B. CSF p-tau (pg/ml), C. ADNI memory z-scores, D. hippocampal

volume (corrected with regression method), E. ADNI executive function z-scores, and F. CSF

amyloid beta (pg/ml) in ADNI participants by sex and number of APOEε4 alleles (0, 1, 2

alelles).

Figure 2. A. ADNI memory z-scores, B. hippocampal volume (corrected with regression

method), C. CSF tau (pg/ml), D. CSF p-tau (pg/ml), E. ADNI executive function z-scores, F.

CSF amyloid beta (pg/ml) in ADNI participants by sex and diagnosis (CN, EMCI, LMCI, AD).

CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive

impairment; AD, Alzheimer's disease.

Figure 1

Figure 2

Table 1. Demographic and clinical information for all participants and subdivided by sex. Biomarkers for AD are from cerebrospinal fluid. P-values adjusted for age are presented for easier comparison and are taken from the linear model of sex and APOE genotype (Table 2). Volume of the hippocampus was corrected using a regression method or using a ratio with intracranial volume (see methods for more details).

	Total No. 1,460	Sex		P-value	P-value (adjusted for age)
		Female No. 630	Male No. 830		
Age					
Mean (SD)	74.13 (±7.25)	73.15 (±7.28)	74.87 (±7.14)	< 0.0001	
Education (years)					
Mean (SD)	15.83 (±2.88)	15.15 (±2.79)	16.34 (±2.85)	< 0.0001	
Ethnicity					
White	1,352 (92.60%)	573 (90.95%)	779 (93.86%)	0.043	
Not white	108 (7.40%)	57 (9.05%)	51 (6.14%)		
Baseline diagnosis					
CN	341 (23.4%)	168 (26.7%)	173 (20.8%)	0.013	
EMCI	257 (17.6%)	108 (17.1%)	149 (18.0%)		
LMCI	533 (36.5%)	205 (32.5%)	328 (39.5%)		
AD	329 (22.5%)	149 (23.7%)	180 (21.7%)		
APOEε4 allele number					
0	702 (48.08%)	300 (47.62%)	402 (48.43%)	0.8	
1	574 (39.32%)	252 (40.00%)	322 (38.80%)		
2	170 (11.64%)	70 (11.11%)	100 (12.05%)		
Missing	14 (0.96%)	8 (1.27%)	6 (0.72%)		
Volume of hippocampus (uncorrected, mm^3)					
Mean (SD)	6659.47 (±1176.42)	6446.71 (±1169.97)	6822.86 (±1155.87)	< 0.0001	
Missing	226 (15.48%)	94 (14.92%)	132 (15.90%)		
Volume of hippocampus (regression corrected)					
Mean (SD)	6659.47 (±1174.34)	6447.09 (±1167.90)	6822.57 (±1153.83)	**< 0.0001**	**<0.0001**
Missing	226 (15.48%)	94 (14.92%)	132 (15.90%)		
Volume of hippocampus/intracranial volume					
Mean (SD)	0.00436 (±0.00080)	0.00454 (±0.00082)	0.00423 (±0.00076)	**< 0.0001**	**<0.0001**
Missing	226 (15.48%)	94 (14.92%)	132 (15.90%)		
Amyloid Beta					
Mean (SD)	830.97 (±358.04)	856.41 (±346.87)	812.44 (±365.16)	**0.016**	0.38
Missing	513 (35.14%)	231 (36.67%)	282 (33.98%)		
Tau					
Mean (SD)	294.38 (±137.27)	314.56 (±152.70)	279.70 (±122.91)	**0.002**	**<0.0001**
Missing	513 (35.14%)	231 (36.67%)	282 (33.98%)		
PTau					
Mean (SD)	28.89 (±15.31)	30.87 (±16.95)	27.44 (±13.83)	**0.007**	**<0.0001**
Missing	513 (35.14%)	231 (36.67%)	282 (33.98%)		
Executive Function (ADNI_EF)					
Mean (SD)	0.02 (±0.96)	0.06 (±0.97)	-0.00 (±0.95)	0.20	**<0.0001**
Missing	311 (21.30%)	145 (23.02%)	166 (20.00%)		
Memory (ADNI_MEM)					
Mean (SD)	0.10 (±0.87)	0.21 (±0.94)	0.02 (±0.80)	**0.0006**	**<0.0001**
Missing	310 (21.23%)	145 (23.02%)	165 (19.88%)		

P-values are from Wilcoxon rank sum tests for continuous variables and Fisher's exact tests for categorical variables. Missing refers to number of individuals and the percent of the total cohort that had missing data for that variable

Table 2. Linear regression results for models with sex and APOE status.P-values are for overall tests and are FDR-adjusted.

Predictors	ADNI MEM Estimates (CI)	adjusted p	ADNI EF Estimates (CI)	adjusted p	ABETA Estimates (CI)	adjusted p	Hippocampus volume (regression method) Estimates (CI)	adjusted p	Hippocampus/Intracranial volume Estimates (CI)	adjusted p	TAU Estimates (CI)	adjusted p	PTAU Estimates (CI)	adjusted p
(Intercept)	1.63 (1.12 – 2.14)		2.05 (1.47 – 2.62)		1458.67 (1247.77 – 1669.57)		(10935.47 – 12165.88)		0.00752 (0.00709 – 0.00795)		56.15 (-30.03 – 142.34)		4.75 (-4.89 – 14.38)	
AGE (years)	-0.02 (-0.02 – -0.01)		-0.02 (-0.03 – -0.02)		-6.19 (-9.01 – -3.36)		-65.72 (-73.95 – -57.49)		-0.00004 (-0.0004 – -0.0003)		2.68 (1.54 – 3.81)		0.26 (0.13 – 0.39)	
Male (ref = Female)	-0.17 (-0.26 – -0.07)	**0.003**	-0.03 (-0.14 – 0.08)	0.73	-29.77 (-71.55 – 12.01)	0.33	482.18 (365.03 – 599.32)	**<0.0001**	-0.00024 (-0.00033 – -0.00016)	**<0.0001**	-7.37 (-31.43 – 16.70)		-0.34 (-3.03 – 2.35)	
APOE status (ref = 0 alleles)		**<0.0001**		**<0.0001**		**<0.0001**		**<0.0001**		**<0.0001**				
1 allele	-0.45 (-0.55 – -0.34)		-0.3 (-0.42 – -0.19)		-240.23 (-284.27 – -196.20)		-518.73 (-642.15 – -395.31)		-0.00031 (--0.0004 – -0.00022)		104.14 (77.21 – 131.06)		11.73 (8.72 – 14.74)	
2 alleles	-0.69 (-0.85 – -0.53)		-0.46 (-0.64 – -0.28)		-455.95 (-521.02 – -390.88)		-946.01 (-1136.77 – -755.25)		-0.00057 (-0.00071 – --0.00044)		178.88 (137.45 – 220.31)		19.81 (15.18 – 24.44)	
Interaction term												**0.001**		**0.002**
Male:1 allele											-49.76 (-85.30 – -14.22)		-5.58 (-9.55 – -1.60)	
Male:2 alleles											-101.56 (-153.97 – -49.16)		-10.78 (-16.64 – -4.92)	
Observations		1145		1144		947		1224		1224		947		947
R^2 / adjusted R^2	0.106 / 0.103		0.058 / 0.055		0.203 / 0.199		0.233/0.231		0.191/0.189		0.140 / 0.134		0.136 / 0.130	

Table 3. Linear regression results for models with sex and baseline diagnosis. P-values are for overall tests and are FDR-adjusted.

Predictors	ADNI MEM Estimates (CI)	adjusted p	ADNI EF Estimates (CI)	adjusted p	ABETA Estimates (CI)	adjusted p	Hippocampus volume (regression method) Estimates (CI)	adjusted p	Hippocampus/Intracranial volume Estimates (CI)	adjusted p	TAU Estimates (CI)	adjusted p	PTAU Estimates (CI)	adjusted p
(Intercept)	1.79 (1.45 – 2.13)		2.26 (1.80 – 2.73)		1161.57 (944.04 – 1379.10)		11424.98 (10886.11 – 11963.86)		0.00747 (0.00710 – 0.00785)		154.16 (70.57 – 237.75)		15.72 (6.36 – 25.09)	
AGE (years)	-0.01 (-0.01 – -0.00)		-0.02 (-0.03 – -0.01)		-1.64 (-4.52 – 1.24)		-57.95 (-65.07 – -50.83)		-0.00003 (-0.00004 – -0.00003)		1.25 (0.15 – 2.36)		0.1 (-0.02 – 0.23)	
Male (ref = Female)	-0.16 (-0.23 – -0.09)	<0.0001	-0.04 (-0.13 – 0.05)	0.56	-26.62 (-69.46 – 16.22)	0.42	516.27 (414.05 – 618.49)	<0.0001	-0.00022 (-0.00029 – -0.00015)	<0.0001	-42.59 (-59.05 – -26.13)	<0.0001	-4.22 (-6.06 – -2.38)	<0.0001
Diagnosis (ref = CN)		<0.0001		<0.0001		<0.0001		<0.0001		<0.0001		<0.0001		<0.0001
EMCI	-0.5 (-0.61 – -0.39)		-0.42 (-0.56 – -0.27)		-85.2 (-148.82 – -21.59)		-340.14 (-495.23 – -185.04)		-0.00016 (-0.00027 – -0.00005)		37.85 (13.41 – 62.30)		4.22 (1.48 – 6.96)	
LMCI	-1.08 (-1.16 – -1.00)		-0.79 (-0.90 – -0.67)		-256.85 (-315.81 – -197.89)		-1049.98 (-1183.33 – -916.63)		-0.00073 (-0.00083 – -0.00064)		93.34 (70.69 – 116.00)		10.58 (8.05 – 13.12)	
AD	-1.84 (-1.94 – -1.75)		-1.63 (-1.76 – -1.50)		-390.48 (-453.59 – -327.37)		-1603.56 (-1751.83 – -1455.29)		-0.00106 (-0.00116 – -0.00096)		143.6 (119.35 – 167.86)		15.81 (13.10 – 18.53)	
Observations	1150		1149		947		1234		1234		947		947	
R² / adjusted R²	0.589 / 0.588		0.380 / 0.377		0.168 / 0.164		0.416/ 0.414		0.398 / 0.396		0.164 / 0.160		0.156 / 0.152	